|
|
|
|
| LEADER |
02714nam a2200397 u 4500 |
| 001 |
EB000942782 |
| 003 |
EBX01000000000000000736372 |
| 005 |
00000000000000.0 |
| 007 |
tu||||||||||||||||||||| |
| 008 |
150223 r ||| eng |
| 100 |
1 |
|
|a Gartlehner, Gerald
|
| 245 |
0 |
0 |
|a Targeted immune modulators
|h Elektronische Ressource
|b final report update 2
|c Gerald Gartlehner ... [et al.] ; produced by RTI-UNC Evidence-based Practice Center, Cecil G. Sheps Center for Health Services Research, University of North Carolina at Chapel Hill ... [et al.]
|
| 246 |
3 |
1 |
|a targeted immune modulators
|
| 260 |
|
|
|a Portland, Or.
|b Oregon Health & Science University
|c c2009, 2009
|
| 300 |
|
|
|a 1 PDF file (637 p.)
|
| 505 |
0 |
|
|a Includes bibliographical references
|
| 653 |
|
|
|a Drug Evaluation
|
| 653 |
|
|
|a Inflammatory Bowel Diseases / drug therapy
|
| 653 |
|
|
|a Clinical Trials as Topic
|
| 653 |
|
|
|a Immunologic Factors / therapeutic use
|
| 653 |
|
|
|a Immunoconjugates / therapeutic use
|
| 653 |
|
|
|a Arthritis / drug therapy
|
| 700 |
1 |
|
|a Gartlehner, Gerald
|
| 710 |
2 |
|
|a Drug Effectiveness Review Project
|
| 710 |
2 |
|
|a Research Triangle Institute-University of North Carolina Evidence-based Practice Center
|
| 710 |
2 |
|
|a Oregon Health & Science University
|
| 710 |
2 |
|
|a Oregon Health & Science University
|b Evidence-based Practice Center
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b NCBI
|a National Center for Biotechnology Information
|
| 490 |
0 |
|
|a Drug class review
|
| 500 |
|
|
|a "November 2009.". - Title from PDF cover (viewed May 17, 2011)
|
| 856 |
4 |
0 |
|u https://www.ncbi.nlm.nih.gov/books/NBK47225
|3 Volltext
|n NLM Bookshelf Books
|3 Volltext
|
| 856 |
4 |
0 |
|u https://www.ncbi.nlm.nih.gov/books/NBK47225/pdf/TOC.pdf
|3 Volltext
|n NLM Bookshelf Books
|3 Volltext
|
| 082 |
0 |
|
|a 700
|
| 082 |
0 |
|
|a 610
|
| 520 |
|
|
|a Targeted immune modulators, commonly referred to as biological response modifiers or simply biologics, are a relatively new category of medications used in the treatment of certain types of immunologic and inflammatory diseases, including rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, plaque psoriasis, Crohn's disease, and ulcerative colitis. The US Food and Drug Administration approved the first of the biologics (infliximab) in 1998 and approved 9 additional agents since that time for treating various rheumatic conditions and plaque psoriasis: etanercept (1998), anakinra (2001), adalimumab (2002), alefacept (2003), efalizumab (2003), abatacept (2005), rituximab (2006), natalizumab (2008), and certolizumab pegol (2008). In this report, we review the comparative effectiveness, safety, and tolerability of targeted immune modulators
|